Group 1 - The company, Jiukang Biotechnology, announced that the period for triggering the conversion price adjustment condition starts from August 27, 2025, and ends on September 11, 2025 [1] - During this period, the company's stock has had ten trading days where the closing price was below 85% of the current conversion price, which is 14.43 yuan per share from August 27 to September 4, 2025, and 14.18 yuan per share from September 5, 2025 [1] - If the conversion price adjustment condition is triggered, the company will follow the relevant regulations of the Shenzhen Stock Exchange and the provisions of the prospectus for the issuance of convertible bonds to perform subsequent review procedures and information disclosure obligations [1]

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-075 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于"九强转债"预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 2025 年 7 月 23 日至 2025 年 9 月 4 日为人民币 16.98 元/股 4、转股起止时间：2023 年 1 月 6 日至 2028 年 6 月 29 日 5、本次触发转股价格修正条件的期间从 2025 年 8 月 27 日起算，截至 2025 年 9 月 11 日，公司股票在连续三十个交易日中已有十个交易日的收盘价低于当 前转股价格的 85%（2025 年 8 月 27 日至 2025 年 9 月 4 日为 14.43 元/股，2025 年 9 月 5 日起为 14.18 元/股），预计后续可能触发转股价格向下修正条件。若 触发转股价格修正条件，北京九强生物技术股份有限公司（以下简称"公司"） 将按照深圳证券交 ...

Core Insights - The major shareholders of Jiukang Bio have not reduced their holdings as the deadline for share reduction has passed [1] Shareholder Information - Zou Zuo Jun holds 39.28 million shares, accounting for 6.72% of the company [1] - Liu Xi holds 67.01 million shares, accounting for 11.46% of the company [1] - Luo Ai Ping holds 56.98 million shares, accounting for 9.74% of the company [1] - Sun Xiao Lin holds 50.39 million shares, accounting for 8.62% of the company [1]

公司于2025年9月9日分别收到持股5%以上股东、董事长邹左军先生，持 股5%以上股东、董事刘希先生，持股5%以上股东、董事罗爱平先生，持股5% 以上股东、董事孙小林先生分别出具的《股份减持实施情况告知函》，现将 有关情况公告如下： 一、减持计划的具体实施情况 证券代码：300406 证券简称：九强生物 公告编号：2025-074 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 关于持股5%以上股东、董事减持计划期限届满未减持股份的公告 持股 5%以上股东、董事长邹左军先生，持股 5%以上股东、董事刘希先生，持股 5%以上股东、董事罗爱平先生，持股 5%以上股东、董事孙小林先生保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 北京九强生物技术股份有限公司(以下简称"公司"或"九强生物")于 2025年5月16日披露了《关于持股5%以上股东、董事减持股份预披露公告》（公 告编号：2025-043）。 截至2025年9月9日，本次股份减持计划期限已届满，邹左军先生、刘希 先生、罗爱平先生 ...

Group 1 - Matrix Co., Ltd. announced that its wholly-owned subsidiary, Anke Technology, introduced a strategic investor, Shenzhen Jifu New Industry Venture Capital Fund, which invested 5 million yuan for a 10% stake [1] - Heng Rui Medicine received approval from the National Medical Products Administration for its Eicosapentaenoic Acid Ethyl Ester Soft Capsule, aimed at reducing triglyceride levels in patients with severe hypertriglyceridemia [1] - Mo Gao Co., Ltd. announced the resignation of its Vice President Jin Baoshan due to job transfer [1] Group 2 - Yao Wang Technology decided to terminate two fundraising projects and will permanently supplement the remaining funds into working capital [2] - Minhe Livestock reported sales of 25.53 million chicklings in August, generating revenue of 86.41 million yuan, with year-on-year growth of 27.60% [2] - Sichuan Jinding announced the resignation of its Director and General Manager Xiong Jifeng due to personal reasons [3] Group 3 - Taiji Group received approval for clinical trials of its Semaglutide Injection, aimed at blood sugar control in type 2 diabetes patients [5] - Jieput announced plans to increase capital in its affiliate, Suidong Intelligent Technology, with an investment of 5 million yuan for a 5% stake [7] - GeLing Deep Vision's controlling shareholders committed not to reduce their shareholdings for six months starting from September 17, 2025 [8] Group 4 - Huafeng Superfiber reported the resignation of its Vice President Liu Cong due to personal reasons [9] - Xiaoming Co., Ltd. reported sales revenue of 79.90 million yuan from chicken products in August, with year-on-year growth of 11.73% [11] - Lion Head Co., Ltd. announced that its application for issuing shares and cash to acquire assets has been accepted by the Shanghai Stock Exchange [12] Group 5 - Jinlong Automobile reported a bus sales volume of 4,074 units in August, a year-on-year increase of 23.6% [43] - Metro Design signed a contract for the Ho Chi Minh City urban rail transit project in Vietnam, with a total amount of 1.754 trillion VND [45] - North New Road and Bridge announced winning a mining construction project worth 504 million yuan [28]

Group 1 - The company, Jiukang Bio, announced the receipt of medical device registration certificates from the Beijing Drug Administration for two products: the fully automatic coagulation analyzer (model MDC7600) and the fully automatic chemiluminescence immunoassay analyzer (model Gi 6000) [1] - The fully automatic coagulation analyzer is designed for quantitative analysis of substances in human samples when used with compatible reagents [1] - The fully automatic chemiluminescence immunoassay analyzer utilizes an indirect chemiluminescence method based on AMPPD and alkaline phosphatase, and is used in clinical settings for qualitative or quantitative detection of analytes in various human samples, including serum, plasma, whole blood, urine, and cerebrospinal fluid [1] Group 2 - The analytes that can be detected by the fully automatic chemiluminescence immunoassay analyzer include vitamins, amino acids, drug concentrations, hormones, myocardial diseases, infectious diseases, autoantibodies, tumor-related antigens, proteins and peptides, kidney diseases, liver diseases, immune function assessments, allergen-related projects, coagulation tests, and other enzyme assays [1]

Core Viewpoint - The company, Jiukang Biological, has received medical device registration certificates for two products, which is expected to enhance its core competitiveness and positively impact future development [1]. Product Development - The company has obtained registration certificates for the following products: - Fully automatic coagulation analyzer (Model MDC7600) - Fully automatic chemiluminescence immunoassay analyzer (Model Gi6000) [1]. Competitive Advantage - The acquisition of these medical device registration certificates enriches the company's product categories, thereby strengthening its core competitiveness [1].

Core Insights - The company, 九强生物 (300406.SZ), has recently received a medical device registration certificate from the Beijing Drug Administration for two products: the fully automated coagulation analyzer (model MDC7600) and the fully automated chemiluminescence immunoassay analyzer (model Gi6000) [1] Product Development - The acquisition of the medical device registration certificate enhances the company's product portfolio [1] - The new products are expected to strengthen the company's core competitiveness [1] Future Outlook - The approval of these medical devices is anticipated to have a positive impact on the company's future development [1]

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-073 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 董事会 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： 2025年9月9日 | 序号 | 产品名称 | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | 全自动凝血分析仪 （型号 MDC7600） | 京 械 注 准 20252220804 | Ⅱ | 自批准之日起 有效期至 2030 年 09 月 04 日 | 与适配试剂配合使用，用于人体样本 中待测物的定量分析。 | | | | | | | 该产品采用基于 AMPPD 和碱性磷酸 酶的间接化学发光法，与配套的检测 | | | | | | | 试剂共同使用，在临床上用于对来 ...

Core Points - The company announced the resignation of Liang Hongjun from multiple positions including Vice Chairman, Director, and General Manager due to work relocation [1] - Following his resignation, Liang Hongjun will no longer hold any positions within the company or its subsidiaries, and his departure has been processed according to relevant regulations [1]